Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 3/20 | 0.51 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307128 | 0.85 | DPP4 (0.50) | PRPS1DPP4DPP8LMNAADORA2B | |
| SCHEMBL307323 | 0.84 | DPP4 (0.52) | PRPS1DPP4DPP8TRPV1LMNA | |
| SCHEMBL307334 | 0.80 | DPP4 (0.45) | PRPS1DPP4DPP8LMNAADORA2B | |
| SCHEMBL307885 | 0.78 | TRPV1 (0.53) | PRPS1TRPV1LMNAADORA2BCSNK2A2 | |
| SCHEMBL3029115 | 0.73 | PRPS1 (0.51) | PRPS1DPP4DPP8LMNAADORA2B | |
| SCHEMBL14291769 | 0.71 | DPP4 (0.49) | PRPS1DPP4DPP8LMNAADORA2B | |
| SCHEMBL7033563 | 0.71 | DPP4 (0.46) | PRPS1DPP4DPP8LMNAADORA2B | |
| SCHEMBL308832 | 0.70 | DPP4 (0.58) | PRPS1DPP4DPP8LMNAADORA2B | |
| SCHEMBL9597231 | 0.70 | TDP1 (0.44) | PRPS1LMNATDP1 | |
| SCHEMBL3037931 | 0.70 | PRPS1 (0.54) | PRPS1DPP4DPP8LMNAADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| EP-1966156-B1 | NEW COMPOUNDS III | ASTRAZENECA AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1966156-A2 | NEW COMPOUNDS III | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221188-A1 | New Benzimidazole Derivatives | OPRD1, OPRK1, SDHA | PRPS1 3338/4885DPP4 1151/4885DPP8 1235/4885 |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | OPRD1, OPRK1, SDHA | PRPS1 2998/4885DPP4 913/4885DPP8 1054/4885 |
| US-20080171770-A1 | Compounds | REN, PCSK9, SLC10A1 | PRPS1 2928/4885DPP4 58/4885DPP8 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.